CLOV vs GRAL: Which Stock Is the Better Buy?
Clover Health Investments, Corp. and GRAIL, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CLOV vs GRAL, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Clover Health Investments, Corp. (CLOV) | GRAIL, Inc. (GRAL) | |
|---|---|---|
| Market cap | $2.6B | $2.6B |
| Revenue (latest FY) | $1.92B | $147.17M |
| Net income (latest FY) | $-85.55M | $-408.35M |
| Revenue growth (5y CAGR) | 23.4% | 38.4% |
| Net margin | -4.4% | -277.5% |
| Return on equity | -27.7% | -15.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full CLOV vs GRAL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CLOV's full financials → Open GRAL's full financials →More comparisons
Frequently asked questions
Which is bigger, CLOV or GRAL?
GRAIL, Inc. is larger by market capitalization — $2.6B versus $2.6B.
Which grows faster, CLOV or GRAL?
Over the last five fiscal years, GRAIL, Inc. grew revenue faster — 38.4%/yr versus 23.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
CLOV fundamentals → · GRAL fundamentals → · All 1,500+ companies → · Free screener →